Basel Medical Group Ltd Ordinary Shares(BMGL)Earnings, Financials & Key Ratios
BMGL•NASDAQ•Insurance & Managed Care
$7.04
Price updated Jul 6, 2026
AboutBasel Medical Group Ltd provides healthcare services. The company offers services in the areas of medical specialists, medical supplies and equipment, medical technology, and pharmaceuticals. The company was incorporated in 2023 and is based in Singapore.Show more
- Revenue$11M+12.6%
- Combined Ratio119.28%+52.6%
- Net Income-$12M-683.2%
- Return on Equity-194.55%-712.5%
- Medical Cost Ratio22.32%-0.2%
- Operating Margin-19.28%-188.3%
- Net Margin-106.78%-617.8%
- ROA-72.9%-657.2%
- Equity / Assets28.86%-37.8%
BMGL Price & Volume
Basel Medical Group Ltd Ordinary Shares (BMGL) stock price & volume — 10-year historical chart
Loading chart...
Unsustainable Underwriting Losses Threaten Capital Base Stability
Investment Thesis • Updated 2024Q4
VerdictNegative
Growth:Expanding
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Unsustainable capital burn rate
Key Thesis Takeaways
- Basel Medical Group faces significant structural headwinds as its 126.7% combined ratio indicates a fundamental inability to achieve underwriting profitability.
- The company's reliance on external capital to fund operations, evidenced by a -106.78% net margin, suggests that the current business model is not yet viable.
- Investors should monitor the firm's ability to manage its $5.4M in loss reserves against a negligible $49 investment portfolio, which may indicate severe liquidity risks.
Verdict Logic
the company's 126.7% combined ratio and lack of a liquid asset buffer suggest that the current operational trajectory is unsustainable for long-term equity holders.
BMGL Growth Metrics
Basel Medical Group Ltd Ordinary Shares (BMGL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years2.03%
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-
Return on Capital
10 Years10.75%
5 Years10.75%
3 Years5.79%
Last Year-28.52%
Peers Comparison
Key metrics vs top competitors for Basel Medical Group Ltd Ordinary Shares (BMGL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $7.04 | $11.02M | -1.76 | 12.63% | -106.78% | -194.55% | — | |
| $98.52 | $6.52B | 71.91 | 15.24% | 9.48% | 5.13% | — | |
| $5.06 | $2.62B | -29.76 | 40.34% | -2.58% | -17.08% | — | |
| $8.69 | $9.78M | -0.23 | -83.94% | — | — | — | |
| $0.96 | $32.96K | -0.00 | -69.88% | -569.09% | -134.41% | — | |
| $27.39 | $2.28B | 14.12 | -4.92% | 9.02% | 20.09% | — |
Compare BMGL vs Peers
Basel Medical Group Ltd Ordinary Shares (BMGL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when BMGL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BMGL Frequently Asked Questions
Basel Medical Group Ltd Ordinary Shares (BMGL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
How fast is Basel Medical Group Ltd Ordinary Shares growing?
Basel Medical Group Ltd Ordinary Shares (BMGL) grew revenue by 12.6% over the past year. This is steady growth.
Is BMGL profitable?
Basel Medical Group Ltd Ordinary Shares (BMGL) reported a net loss of $12.1M for fiscal year 2024.
Dividend & Returns
What is BMGL's return on equity?
Basel Medical Group Ltd Ordinary Shares (BMGL) has a return on equity (ROE) of -194.6%. Negative ROE indicates the company is unprofitable.
Industry Metrics
What is Basel Medical Group Ltd Ordinary Shares's combined ratio?
Basel Medical Group Ltd Ordinary Shares (BMGL) has a combined ratio of 119.3%. A ratio above 100% means claims and expenses exceed premiums.